[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck
- PMID: 18006761
- DOI: 10.1158/1078-0432.CCR-07-0528
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck
Abstract
Purpose: [(18)F]Galacto-RGD has been developed for positron emission tomography (PET)-imaging of alphavbeta3 expression, a receptor involved in angiogenesis and metastasis. Our aim was to study the feasibility of PET imaging with [(18)F]Galacto-RGD in patients with squamous cell carcinoma of the head and neck (SCCHN).
Experimental design: Eleven patients with primary diagnosis of SCCHN were examined. After injection of 140 to 200 MBq [(18)F]Galacto-RGD, static emission scans 60 min post injection from the head to the abdomen (n = 11) and dynamic scans >60 min covering the tumor region (n = 6) for kinetic modeling were acquired. Standardized uptake values (SUV) were measured in tumors, muscle and oral mucosa. Immunohistochemistry was done using an alphavbeta3-specific antibody (n = 7). Image fusion with magnetic resonance imaging and/or computed tomography (CT) scans (n = 8) and calculation of tumor subvolumes based on SUVs was done using the iPlan software (BrainLAB).
Results: [(18)F]Galacto-RGD PET identified 10 of 12 tumors, with SUVs ranging from 2.2 to 5.8 (mean, 3.4 +/- 1.2). Two tumors <5 mm were missed. Tumor/blood and tumor/muscle ratios were 2.8 +/- 1.1 and 5.5 +/- 1.6, respectively. Tumor kinetics was consistent with a two-tissue compartmental model with reversible specific binding. Immunohistochemistry confirmed alphavbeta3 expression in all tumors with alphavbeta3 being located on the microvessels in all specimens and additionally on tumor cells in one specimen. Image fusion of [(18)F]Galacto-RGD PET with magnetic resonance imaging/multislice CT and definition of tumor subvolumes was feasible in all cases.
Conclusions: [(18)F]Galacto-RGD PET allows for specific imaging of alphavbeta3 expression in SCCHN with good contrast. Image fusion and definition of tumor subvolumes is feasible. This technique might be used for the assessment of angiogenesis and for planning and response evaluation of alphavbeta3-targeted therapies.
Similar articles
-
PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis.JACC Cardiovasc Imaging. 2014 Feb;7(2):178-87. doi: 10.1016/j.jcmg.2013.12.003. Epub 2014 Jan 8. JACC Cardiovasc Imaging. 2014. PMID: 24412187
-
PET monitoring of therapy response in head and neck squamous cell carcinoma.J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380408 Review.
-
Imaging of integrin alphavbeta3 expression.Cancer Metastasis Rev. 2008 Dec;27(4):631-44. doi: 10.1007/s10555-008-9158-3. Cancer Metastasis Rev. 2008. PMID: 18523730 Review.
-
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.Clin Cancer Res. 2006 Jul 1;12(13):3942-9. doi: 10.1158/1078-0432.CCR-06-0266. Clin Cancer Res. 2006. PMID: 16818691
-
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.J Nucl Med. 2005 Aug;46(8):1333-41. J Nucl Med. 2005. PMID: 16085591 Clinical Trial.
Cited by
-
Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models.Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):54-67. doi: 10.1007/s00259-023-06412-z. Epub 2023 Aug 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37642706
-
Improved Boron Neutron Capture Therapy Using Integrin αvβ3-Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model.Biology (Basel). 2023 Feb 27;12(3):377. doi: 10.3390/biology12030377. Biology (Basel). 2023. PMID: 36979069 Free PMC article.
-
Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.Int J Mol Sci. 2023 Jan 5;24(2):1079. doi: 10.3390/ijms24021079. Int J Mol Sci. 2023. PMID: 36674595 Free PMC article. Review.
-
Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.Int J Nanomedicine. 2022 Sep 15;17:4293-4306. doi: 10.2147/IJN.S377816. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36134201 Free PMC article. Review.
-
Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.J Transl Med. 2022 Aug 12;20(1):358. doi: 10.1186/s12967-022-03559-5. J Transl Med. 2022. PMID: 35962347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical